Giralt, S A <br/><br/>
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Apr 2011 
 - 939-946 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdq457  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Isoquinolines--administration & dosage<br/>Male<br/>Melphalan--administration & dosage<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Nausea--chemically induced<br/>Palonosetron<br/>Quinuclidines--administration & dosage<br/>Vomiting--chemically induced